Advertisement

Ipilimumab

  • Giuseppe Tridente
Chapter

Abstract

Ipilimumab (Yervoy®, BMS), previously known as MDX-010 or BMS-734016, is a fully human IgG1k directed to the extracellular domain of CTLA-4 (cytotoxic T cell antigen-4, or CD152) present on activated T cells [1, 2, 3, 4, 5]. FDA licensed the product for the treatment of unresectable or metastatic melanoma (mMM) in 2011. During the same year, EMEA granted approval for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy. Meanwhile, TGA (Australia) granted approval for the treatment of patients with advanced melanoma in whom previous therapies failed or were not tolerated. However, at that time, NICE recommended the UK National Health Service against using ipilimumab, due to lack of biomarkers (the drug was found active only in part of the patients), and due to the severity of potential AEs. In 2012, Health Canada indicated ipilimumab for the treatment of patients with unresectable or metastatic melanoma in whom other systemic therapy for advanced disease failed or were not tolerated.

Keywords

Metastatic Melanoma Adrenal Insufficiency Toxic Epidermal Necrolysis Intestinal Perforation Ocular Melanoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

307171_1_En_25_MOESM1_ESM.xls (66 kb)
Supplementary material 1 (XLS 67 kb)

References

  1. 1.
    Ipilimumab (Yervoy®) BLA 1253770 Medical Review, FDA Mar 2011Google Scholar
  2. 2.
    Ipilimumab (Yervoy®) WC500109302 Assessment Report, EMEA May 2011Google Scholar
  3. 3.
    Ipilimumab (Yervoy®) SBD 138178 Health Canada, July 2012Google Scholar
  4. 4.
    Ipilimumab (Yervoy®) Product Information, BMS Oct 2012Google Scholar
  5. 5.
    Ipilimumab (Yervoy®) WC 500109299 EPAR Product Information, EMEA July 2012Google Scholar
  6. 6.
    Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526PubMedCrossRefGoogle Scholar
  7. 7.
    Peggs KS, Quezada SA, Chambers CA et al (2009) Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. JEM 206:1717–1725CrossRefGoogle Scholar
  8. 8.
    Verschraegen C (2012) The monoclonal antibody to cytotoxic T lymphocyte antigen 4, Ipilimumab, in the treatment of melanoma. Cancer Manag Res 4:1–8PubMedGoogle Scholar
  9. 9.
    Zhou G, Levitsky H (2012) Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. Clin Develop Immunol. doi: 10.1155/2012/124187 Google Scholar
  10. 10.
    Jeter JM, Cranmer LD, Hersh EM (2012) Ipilimumab pharmacotherapy in patients with metastatic melanoma. Clin Med Insights Oncol 6:275–286PubMedGoogle Scholar
  11. 11.
    Wolchock J, Neyns B, Linette G et al (2009) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomized, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155–164CrossRefGoogle Scholar
  12. 12.
    Jeter J, Cranmer LD, Hersch EM (2012) Ipilimumab pharmacotherapy in patients with metastatic melanoma. Clin Med Insights Oncol 6:275–286PubMedGoogle Scholar
  13. 13.
    O’Regan KN, Jagannathan JP, Ramaiya N et al (2011) Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing Ipilimumab therapy. AJR 197:W241–W246PubMedCrossRefGoogle Scholar
  14. 14.
    Min L, Vaidya A, Becker C (2012) Association of Ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocr Pract 18:351–355PubMedCrossRefGoogle Scholar
  15. 15.
    Rao AR, Grumett SA (2013) Ipilimumab associated autoimmune alveolitis responding to corticosteroids. J Med Cases 4:22–25Google Scholar
  16. 16.
    Di Giacomo AM, Ascierto PA, Pilla L et al (2012) Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 13:879–886PubMedCrossRefGoogle Scholar
  17. 17.
    Torino F, Bernabei A, De Vecchis L et al (2012) Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist 17:525–535PubMedCrossRefGoogle Scholar
  18. 18.
    Small EJ, Tchekmedyian NS, Rini BI et al (2007) A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13:1810–1815PubMedCrossRefGoogle Scholar
  19. 19.
    Madan RA, Mohebtash M, Arlen PM et al (2012) Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 13:501–508PubMedCrossRefGoogle Scholar
  20. 20.
    Van den Eertwegh AJM, Versluis J, van den Berg HP et al (2012) Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 13:509–517PubMedCrossRefGoogle Scholar
  21. 21.
    Lynch TJ, Bondarenko Luft A et al (2012) Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30:2046–2054PubMedCrossRefGoogle Scholar
  22. 22.
    Danielli R, Ridolfi R, Chiarion-Sileni V et al (2012) Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother 61:41–48PubMedCrossRefGoogle Scholar
  23. 23.
    Sarnaik AA, Yu B, Yu D et al (2011) Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res 17:896–906PubMedCrossRefGoogle Scholar
  24. 24.
    Bakacs T, Mehrishi JN, Szabó M et al (2012) Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy). Pharmacol Res 66:192–197PubMedCrossRefGoogle Scholar
  25. 25.
    Wolchok J (2012) How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Ann Oncol. doi: 10.1093/annonc/mds258 PubMedGoogle Scholar
  26. 26.
    Revicki DA, van den Eertwegh AJM, Lorigan P et al (2012) Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual Life Outcomes 10:66–73PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations